ENTRADA THERAPEUTICS, INC. Proceeds from Common Stock Issued
ENTRADA THERAPEUTICS, INC. (TRDA) reported Proceeds from Common Stock Issued of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-11-06
- ENTRADA THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00.
- ENTRADA THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2024-09-30 was -$392.00K.
- ENTRADA THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2024-06-30 was $100.00M.
- ENTRADA THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month |
|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | ||
| 2024-09-30 | -$392.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $99.61M derived: sum of 2 quarters · filed 2025-11-06 | $99.61M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $100.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $100.00M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $19.41M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $19.41M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $19.41M 10-Q · filed 2024-05-07 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |